An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Status:	Recruiting
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	2/2/2019
Start Date:	March 1, 2018
End Date:	July 5, 2023
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information
Email:	Clinical.Trials@bms.com
Phone:	please email:

A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors

The purpose of this study is to determine whether BMS-986258 both by itself and in
combination with Nivolumab is safe and tolerable in the treatment of advanced malignant
tumors

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
recurrent, and/or unresectable) with measurable disease and have at least 1 lesion
accessible for biopsy

- Eastern Cooperative Oncology Group Performance Status of 0 or 1

- Participants must have received, and then progressed, relapsed, or been intolerant to,
at least 1 standard treatment regimen in the advanced or metastatic setting according
to solid tumor histologies

Exclusion Criteria:

- Participants with active, known or suspected autoimmune disease

- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study therapy

- Participants with other active malignancy requiring concurrent intervention

- Participants with active, known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

University of Pittsburgh Medical Center

200 Lothrop St
Pittsburgh, Pennsylvania 15213